Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
An announcement from Bioxyne Limited ( (AU:BXN) ) is now available.
Bioxyne Limited has released an addendum to its November 2024 investor presentation, highlighting its progress towards achieving a revenue target of over A$20 million. The company reported a revenue of approximately A$12.5 million for the first half of FY2025 and announced the commissioning of a new manufacturing facility to double its capacity. With a diverse customer base and significant supply agreements, Bioxyne is well-positioned to meet its forecasted revenues over two years, driven by strong demand and expanded manufacturing capabilities.
More about Bioxyne Limited
Bioxyne Limited is an Australian life sciences and health products company, which acquired Breathe Life Sciences (BLS) in June 2023. The company focuses on manufacturing and distributing novel pharmaceuticals and consumer health products globally, including medical cannabis, psychedelics, and other health products. BLS aims to lead in the Australian market for pharmaceuticals derived from Cannabis, Psilocybe Cubensis, and MDMA, and is a key supplier of CBD and functional mushroom products in the UK and Europe.
YTD Price Performance: -7.41%
Average Trading Volume: 2,038,542
Technical Sentiment Consensus Rating: Sell
Current Market Cap: A$51.23M
Find detailed analytics on BXN stock on TipRanks’ Stock Analysis page.
